Immunology | Approved Drugs | Pipeline Prospector

Celltrion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC

Lead Product(s): Infliximab

Therapeutic Area: Immunology Product Name: Remsima

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 28, 2020

Details:

The positive CHMP opinion recommends expanding the marketing authorisation for the subcutaneous (SC) formulation of Remsima® for use in an additional five indications, including for the treatment of inflammatory bowel disease (IBD) and ankylosing spondylitis.

Entero Healthcare Solutions

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Roche Pharma India Partners with Entero Healthcare Solutions to Improve Access to Nephrology Medicines

Lead Product(s): Mycophenolate Mofetil

Therapeutic Area: Immunology Product Name: Cellcept

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 18, 2020

Details:

Entero will be responsible for promotion, marketing and distribution of Roche Pharma’s key nephrology drugs viz., Mycophenolate Mofetil (Cellcept), Valganciclovir (Valcyte), Epoetin Beta (NeoRecormon), and Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in India.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease

Lead Product(s): Canakinumab

Therapeutic Area: Immunology Product Name: Ilaris

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

Details:

The U.S. Food and Drug Administration approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD).

Schreiner MediPharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Teva Partners with Schreiner MediPharm for Novel Adrenaline Injector Label

Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 08, 2020

Details:

For the emergency drug epinephrine from TEVA, Schreiner MediPharm developed an Autoinjector-Label with special protection against abrasion.

AbbVie Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

AbbVie's RINVOQ Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in RA Patients

Lead Product(s): Upadacitinib

Therapeutic Area: Immunology Product Name: Rinvoq

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 06, 2020

Details:

In SELECT-CHOICE, RINVOQ™ (upadacitinib) met both the primary and key secondary endpoints compared to ORENCIA® (abatacept) on change from baseline in DAS28-CRP at week 12 in patients with rheumatoid arthritis and inadequate response to biologic DMARDs.

AbbVie Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

New Long-Term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis

Lead Product(s): Upadacitinib,Methotrexate

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

Long-term results from the SELECT-COMPARE and SELECT MONOTHERAPY studies showed that RINVOQ™ (upadacitinib, 15 mg) continued to improve signs and symptoms in patients with rheumatoid arthritis through 72 and 84 weeks, respectively.

Celltrion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Celltrion Healthcare Showcases Positive 1-Year Data and Budget Impact Analysis for Novel Subcutaneous Formulation of Infliximab for RA

Lead Product(s): Infliximab

Therapeutic Area: Immunology Product Name: Remsima

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

1-year data from a randomised controlled trial in patients with rheumatoid arthritis (RA) show no impact of body mass index (BMI) on clinical response to subcutaneous infliximab (Remsima® SC / CT-P13 SC).

Eli Lilly

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Lilly's Taltz Outpaces Novartis' Cosentyx with 4th FDA Approval

Lead Product(s): Ixekizumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

This approval is based on the results from the Phase 3 COAST-X trial, which evaluated improvement in signs and symptoms of nr-axSpA as measured by the proportion of patients who achieved ASAS40 response criteria compared to placebo.

Medac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Fresenius Kabi Enters Marketing Agreement For Biosimilar Product

Lead Product(s): Adalimumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Fresenius Kabi AG

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 28, 2020

Details:

Medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with.

Adamis Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Adamis Pharmaceuticals Terminated Distribution and Commercialization Agreement of its SYMJEPI Products with Sandoz

Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Sandoz Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 11, 2020

Details:

Adamis and Sandoz have reached an agreement allowing for the mutually agreed return to Adamis of SYMJEPI products' marketing, promotion and distribution rights and the termination of the deal.

Find

Find Approved Immunology Drugs in Clinical Development

Approved

Product Type

Companies

Celltrion

Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC

Entero Healthcare Solutions

Roche Pharma India Partners with Entero Healthcare Solutions to Improve Access to Nephrology Medicines

Novartis Pharmaceuticals Corporation

FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease

Schreiner MediPharm

Teva Partners with Schreiner MediPharm for Novel Adrenaline Injector Label

AbbVie Inc

AbbVie's RINVOQ Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in RA Patients

AbbVie Inc

New Long-Term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis

Celltrion

Celltrion Healthcare Showcases Positive 1-Year Data and Budget Impact Analysis for Novel Subcutaneous Formulation of Infliximab for RA

Eli Lilly

Lilly's Taltz Outpaces Novartis' Cosentyx with 4th FDA Approval

Medac

Fresenius Kabi Enters Marketing Agreement For Biosimilar Product

Adamis Pharmaceuticals

Adamis Pharmaceuticals Terminated Distribution and Commercialization Agreement of its SYMJEPI Products with Sandoz